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Discussion: Our data show that sub-chronic ketamine results in the elevation in striatal dopamine synthesis capacity and locomotor sensitization and that these effects require midbrain dopamine neuron activation. Furthermore, our data are in support of the hypothesis that NMDA receptor hypofunction on GABAergic interneurons leads to disinhibition of glutamatergic projections and subsequently increase in dopamine neuron activity and dopamine synthesis capacity in projection targets such as the striatum. 
O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC
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Background: It is important to better understand the optimum doses and equivalent doses of antipsychotic drugs. Several methods to understand these relationships have been published, but all these methods have weaknesses. In this paper we present a dose-response meta-analysis which theoretically is the most appropriate method for this purpose.
Methods:
We identified all double-blind, placebo-controlled, studies that compared at least two fixed doses of second-generation antipsychotic drugs or haloperidol in people with acute schizophrenia or with predominant negative symptoms. For this purpose, we searched multiple electronic databases, the website of the FDA, and the clinical trial database clinicaltrials. gov. The method applied was dose response meta-analyses with a spline model. The outcome was the reduction of the PANSS or BPRS total score from baseline or -for negative symptoms -a negative symptom scale. With this method we identified 95% effective doses (these have also been called "near-to-maximum" doses). We applied linear splines to examine whether the dose-response curves had already reached a plateau. Moreover, the identified dose-response relationships of each drug were used to derive risperidone equivalent doses. Results: We identified 67 randomized-controlled trials that were eligible. The following 1mg risperidone equivalent doses were identified: amisulpride 86.6mg/day, aripiprazole 1.9mg/day, asenapine 2.4mg, brexpiprazole 0.56mg clozapine 91mg, haloperidol 1.01mg, iloperidone 3.2mg, lurasidone 23.5mg, olanzapine 2.4mg, paliperidone 13.4/2.1, quetiapine 77mg, risperidone 1mg, sertindole 3.6mg, ziprasidone 30mg. Discussion: From a conceptual point of view, dose-response meta-analysis is the most appropriate method to identify maximally effective doses and equivalent doses. The results of this meta-analysis will be compared with other published methods to define dose-response, in particular the minimum-effective dose method, the classical mean dose method, the daily-defined-doses (DDD) method and expert consensus methods. The results of this analysis are likely to provide information with impact for treatment decisions. Background: The drug-placebo differences ("effect sizes") in acute phase, randomised, double-blind trials have become smaller and smaller over the decades. In a recent meta-regression analysis, it had been shown that the degree of placebo response is the strongest predictor of drug-placebo differences. Thus, the open question now was what the predictors of placebo response are. Methods: Placebo-controlled, randomised, double-blind trials that compared any licensed antipsychotic drug with placebo were searched in multiple electronic databases, the website of the Food and Drug Administration and the clinical trial database ClinicalTrials.gov. The mean change from baseline of the PANSS or the BPRS total score from baseline to endpoint in the placebo-groups was extracted from each identified trial. The outcome was the degree of placebo response measured by the BPRS or PANSS change from baseline to endpoint. 24 patient-, and study design related parameters were analysed as potential predictors of placebo response in univariate and multivariate meta-regression analyses. Results: Of 167 included RCTs 99 provided the necessary data. In univariate analyses more recent publication year, larger sample size (total number of participants and sites), use of PANSS rather than the BPRS, studies conducted outside the US or mixed, shorter wash-out phases and shorter study duration, lower participant mean age and lower mean duration of illness were associated with higher placebo-response. Discussion: This meta-regression included approximately two times more studies than previous attempts to resolve this issue and it is therefore the to date by far largest analysis of this kind. Multiple potential moderators of placebo response were identified. Importantly, these moderators of placebo response were not identical with those identified in a previous analysis 1 as significant moderators of drug-placebo differences in the same dataset. Thus, different factors appear to play a role in this complex area. Background: Long-term maintenance treatment is recommended to control the symptoms of schizophrenia 1,2 ; therefore, safety monitoring for longer than the period required to treat an acute exacerbation is warranted. The aim of the present study (Lighthouse extension; NCT01810783) was to assess the long-term safety and tolerability of open-label treatment with brexpiprazole (flexible dose 1-4 mg/day) in adult patients with schizophrenia. Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at the serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at the 5-HT2A and noradrenaline α1B/2C receptors, all with subnanomolar potency. Brexpiprazole is approved in the US as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) and in the US, Australia and Canada as monotherapy for treatment of schizophrenia. Methods: Patients rolled over into this 52-week open-label study from a randomized, double-blind, placebo-controlled, active referenced, Phase 3 study (Lighthouse 3 ; NCT01810380). The primary endpoint was safety and tolerability. Efficacy was assessed as an exploratory endpoint using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions -Severity of illness (CGI-S) and Improvement (CGI-I) scales, and the Personal and Social Performance (PSP) scale. Changes from baseline were analyzed using a mixed model repeated measurements (MMRM) approach. Results: 210 patients were enrolled, and 101 (48.3%) completed the study. The mean and mean modal doses of brexpiprazole were 3.07mg/day and 3.18mg/day, respectively; at last visit, 50% of the patients received 4mg/ day. Among patients who took ≥1 dose of brexpiprazole, the incidence of discontinuation due to treatment-emergent adverse events (TEAEs) was 17.2%. TEAEs with an incidence of ≥5.0% were schizophrenia
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